(Total Views: 542)
Posted On: 11/13/2021 2:47:42 PM
Post# of 154003
Re: biloxiblues #110429
The article seems to be saying in refernece to leronlimab, Merck either:
1) is considering a buy out of or partnership with Cytodyn or
2) Merck "shoud be" considering a buy out of or partnership with Cytodyn
Yes, it was the first drug mentioned for Merck to consider, in order to keep up with or surpass Phizer.
Interesting also, that cancer was mentioned as another indication for leronlimab.
The author proposes that Merck will need to be acting quickly because the Phizer pill is moving forward quickly.
Let's see, where was is my final dry powder reserve.
https://seekingalpha.com/article/4469170-merc...-dominance
1) is considering a buy out of or partnership with Cytodyn or
2) Merck "shoud be" considering a buy out of or partnership with Cytodyn
Yes, it was the first drug mentioned for Merck to consider, in order to keep up with or surpass Phizer.
Interesting also, that cancer was mentioned as another indication for leronlimab.
The author proposes that Merck will need to be acting quickly because the Phizer pill is moving forward quickly.
Let's see, where was is my final dry powder reserve.
https://seekingalpha.com/article/4469170-merc...-dominance
(3)
(0)
